Trial Profile
A Phase 1 Study of Oral MRX-1024 in Combination With Standard Fractionation Radiation Therapy and High-Dose Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck Following Surgical Resection
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 May 2018
Price :
$35
*
At a glance
- Drugs MRX 1024 (Primary)
- Indications Stomatitis
- Focus Adverse reactions; Pharmacokinetics
- 21 May 2018 New trial record